This study is designed to examine the safety and efficacy of tofacitinib in subjects with active psoriatic arthritis who have previously had an inadequate response to at least one TNF inhibitor either due to lack of efficacy or an adverse event.
Eligible patients will have:
- Active arthritis at screening/baseline as indicated by >/= 3 tender/painful and 3 swollen joints
- Active plaque psoriasis at screening
- Inadequate response or lack of toleration to previously administered TNF inhibitor
Participants will be randomly assigned to one of three dosing patterns for the investigational drug or placebo. The effects of the drug on the disease will be evaluated in addition to studying the safety of the drugs. About 390 patients will enroll at multiple centers. More information can be found here.
